About
Personalized Synthetic Medicines
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
7
As Collaborator
1
Total Enrollment
2,000
By Phase
PHASE3: 1PHASE1/PHASE2: 3PHASE2/PHASE3: 1PHASE2: 1PHASE1: 2
By Status
RECRUITING: 8
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT07015190Lead Sponsor
Neoadjuvant Darovasertib in Primary Uveal Melanoma
PHASE3Recruiting
520 participants
Started: Oct 31, 2025 · Completed: Mar 31, 2031
NCT07174583Lead Sponsor
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
PHASE1/PHASE2Recruiting
90 participants
Started: Oct 14, 2025 · Completed: May 31, 2029
NCT06710847Collaborator
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
PHASE1/PHASE2Recruiting
73 participants
Started: Dec 13, 2024 · Completed: Jun 16, 2028
NCT05987332Lead Sponsor
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
PHASE2/PHASE3Recruiting
420 participants
Started: Oct 31, 2023 · Completed: Jan 15, 2028
NCT05907954Lead Sponsor
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
PHASE2Recruiting
160 participants
Started: Jul 3, 2023 · Completed: Apr 30, 2030
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...